drugset
drugset / Trial / NCT05553366

Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy

NCT05553366 ↗

Phase 3 Completed 1075 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of suzetrigine for acute pain after a bunionectomy.

Timeline

Start
2022-10-03
Primary completion
2023-12-15
Completion
2023-12-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acetaminophen Small molecule 325 mg Oral
Subject Suzetrigine Small molecule 50 mg Oral
Comparator hydrocodone bitartrate Unknown 5 mg Oral

Indications

No indication recorded.